Adma Biologics reported $3.66M in Gross Profit on Sales for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Adma Biologics ADMA:US $ 3.66M 0.15M
Agile Therapeutics AGRX:US 234K 4.42M
Alnylam Pharmaceuticals ALNY:US $ 184.01M 6.38M
Biocryst Pharmaceuticals BCRX:US $ 65.28M 15.6M
Takeda 4502:JP Y 679583M 114674M